Eagle Rock Investment Company, LLC Bristol Myers Squibb CO Transaction History

Eagle Rock Investment Company, LLC

$532 Million
Q1 2024

A detailed history of Eagle Rock Investment Company, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Eagle Rock Investment Company, LLC holds 64,927 shares of BMY stock, worth $2.67 Million. This represents 0.66% of its overall portfolio holdings.

Number of Shares

64,927

Previous 49,149 32.1%

Holding current value

$2.67 Million

Previous $2.52 Million 39.63%

% of portfolio

0.66%

Previous 0.52%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 15, 2024	BUY	$47.98 - $54.4 $757,028 - $858,323	15,778 Added 32.1%	64,927 $3.52 Million
Q4 2023 Jan 12, 2024	SELL	$48.48 - $57.85 $1.94 Million - $2.31 Million	-39,937 Reduced 44.83%	49,149 $2.52 Million
Q3 2023 Oct 10, 2023	SELL	$57.89 - $64.73 $5,094 - $5,696	-88 Reduced 0.1%	89,086 $5.17 Million
Q2 2023 Jul 19, 2023	SELL	$63.71 - $70.74 $110,727 - $122,946	-1,738 Reduced 1.91%	89,174 $5.7 Million
Q1 2023 Apr 10, 2023	SELL	$65.71 - $74.53 $50,465 - $57,239	-768 Reduced 0.84%	90,912 $6.3 Million

Q4 2022 Jan 25, 2023	SELL	$68.48 - $81.09 $27,323 - $32,354	-399 Reduced 0.43%	91,680 $0
Q3 2022 Nov 08, 2022	SELL	$0.13 - $76.84 $730 - $432,071	-5,623 Reduced 5.76%	92,079 $6.55 Million
Q2 2022 Aug 12, 2022	SELL	$72.62 - $79.98 $1.21 Million - $1.33 Million	-16,640 Reduced 14.55%	97,702 $7.52 Million
Q1 2022 May 11, 2022	SELL	$61.48 - $73.72 $2.85 Million - $3.41 Million	-46,284 Reduced 28.81%	114,342 $8.35 Million
Q4 2021 Feb 17, 2022	BUY	$53.63 - $62.52 $8.61 Million - $10 Million	160,626 New	160,626 $10 Million

Others Institutions Holding BMY

# of Institutions

2,552

Shares Held

1.49B

Call Options Held

25.9M

Put Options Held

20M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $87.4B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eagle Rock Investment Company, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eagle Rock Investment Company, LLC with notifications on news.

Account

Eagle Rock Investment Company, LLC Bristol Myers Squibb CO Transaction History